Tags

Type your tag names separated by a space and hit enter

Stable phase post-MI patients have elevated VEGF levels correlated with inflammation markers, but not with atherosclerotic burden.
BMC Cardiovasc Disord. 2014 Nov 22; 14:166.BC

Abstract

BACKGROUND

The role of vascular endothelial growth factor (VEGF) in patients in the stable phase after myocardial infarction (MI) has not yet been explored. Therefore, we compared the values of VEGF in post-MI patients with those obtained in healthy controls. Furthermore, we investigated whether the values of VEGF correlate to either inflammation markers or the atherosclerotic burden.

METHODS

41 male patients (on average 44 years old) in the stable phase after MI (on average 20.5 months after MI) were recruited, while 25 healthy age-matched males served as controls. Plasma levels of VEGF and several markers of inflammation were measured by standard procedures. The atherosclerotic burden was determined by the angiographic severity of coronary atherosclerosis, endothelial dysfunction (measured by ultrasound measurement of the flow mediated dilation of the brachial artery), the intima-media thickness of the common carotid artery and the ankle-brachial pressure index.

RESULTS

VEGF values were significantly elevated in post-MI patients compared to the controls (53.8 ± 42.7 pg/ml vs. 36.3 ± 8.9 pg/ml, p = 0.014). The elevated VEGF values significantly correlated to the (increased) values of the inflammatory molecules interleukin 6 and 8 (r = 0.37, p = 0.017; and r = 0.45, p = 0.003; respectively). In contrast, no correlation was found between VEGF and the parameters of the atherosclerotic burden, although FMD and IMT were significantly impaired in patients.

CONCLUSIONS

We found that plasma levels of VEGF are increased in the stable phase after MI and correlate with inflammation cytokines, but not with the atherosclerotic burden. Thus, this suggests that increased levels of VEGF are a part of ongoing inflammatory activity. Since VEGF in these patients stimulates neovascularization of inflamed plaques and induces their destabilization, the VEGF level can have an important negative prognostic value. Clearly, further studies are needed to clarify the role of VEGF as a prognostic marker.

Authors+Show Affiliations

Department of Vascular Disease, University Clinical Centre, Ljubljana 1000, Slovenia. erzen_b@yahoo.com.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25417001

Citation

ErŽen, Barbara, et al. "Stable Phase post-MI Patients Have Elevated VEGF Levels Correlated With Inflammation Markers, but Not With Atherosclerotic Burden." BMC Cardiovascular Disorders, vol. 14, 2014, p. 166.
ErŽen B, Šilar M, Šabovič M. Stable phase post-MI patients have elevated VEGF levels correlated with inflammation markers, but not with atherosclerotic burden. BMC Cardiovasc Disord. 2014;14:166.
ErŽen, B., Šilar, M., & Šabovič, M. (2014). Stable phase post-MI patients have elevated VEGF levels correlated with inflammation markers, but not with atherosclerotic burden. BMC Cardiovascular Disorders, 14, 166. https://doi.org/10.1186/1471-2261-14-166
ErŽen B, Šilar M, Šabovič M. Stable Phase post-MI Patients Have Elevated VEGF Levels Correlated With Inflammation Markers, but Not With Atherosclerotic Burden. BMC Cardiovasc Disord. 2014 Nov 22;14:166. PubMed PMID: 25417001.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Stable phase post-MI patients have elevated VEGF levels correlated with inflammation markers, but not with atherosclerotic burden. AU - ErŽen,Barbara, AU - Šilar,Mira, AU - Šabovič,Mišo, Y1 - 2014/11/22/ PY - 2014/05/30/received PY - 2014/11/11/accepted PY - 2014/11/24/entrez PY - 2014/11/25/pubmed PY - 2015/5/23/medline SP - 166 EP - 166 JF - BMC cardiovascular disorders JO - BMC Cardiovasc Disord VL - 14 N2 - BACKGROUND: The role of vascular endothelial growth factor (VEGF) in patients in the stable phase after myocardial infarction (MI) has not yet been explored. Therefore, we compared the values of VEGF in post-MI patients with those obtained in healthy controls. Furthermore, we investigated whether the values of VEGF correlate to either inflammation markers or the atherosclerotic burden. METHODS: 41 male patients (on average 44 years old) in the stable phase after MI (on average 20.5 months after MI) were recruited, while 25 healthy age-matched males served as controls. Plasma levels of VEGF and several markers of inflammation were measured by standard procedures. The atherosclerotic burden was determined by the angiographic severity of coronary atherosclerosis, endothelial dysfunction (measured by ultrasound measurement of the flow mediated dilation of the brachial artery), the intima-media thickness of the common carotid artery and the ankle-brachial pressure index. RESULTS: VEGF values were significantly elevated in post-MI patients compared to the controls (53.8 ± 42.7 pg/ml vs. 36.3 ± 8.9 pg/ml, p = 0.014). The elevated VEGF values significantly correlated to the (increased) values of the inflammatory molecules interleukin 6 and 8 (r = 0.37, p = 0.017; and r = 0.45, p = 0.003; respectively). In contrast, no correlation was found between VEGF and the parameters of the atherosclerotic burden, although FMD and IMT were significantly impaired in patients. CONCLUSIONS: We found that plasma levels of VEGF are increased in the stable phase after MI and correlate with inflammation cytokines, but not with the atherosclerotic burden. Thus, this suggests that increased levels of VEGF are a part of ongoing inflammatory activity. Since VEGF in these patients stimulates neovascularization of inflamed plaques and induces their destabilization, the VEGF level can have an important negative prognostic value. Clearly, further studies are needed to clarify the role of VEGF as a prognostic marker. SN - 1471-2261 UR - https://www.unboundmedicine.com/medline/citation/25417001/Stable_phase_post_MI_patients_have_elevated_VEGF_levels_correlated_with_inflammation_markers_but_not_with_atherosclerotic_burden_ L2 - https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/1471-2261-14-166 DB - PRIME DP - Unbound Medicine ER -